Effects of bromocriptine in peripartum cardiomyopathy: a systematic review and meta-analysis

Author(s):  
Angkawipa Trongtorsak ◽  
Veraprapas Kittipibul ◽  
Sunita Mahabir ◽  
Michel Ibrahim ◽  
Garly R. Saint Croix ◽  
...  
2019 ◽  
Vol 112 (3) ◽  
pp. 187-198 ◽  
Author(s):  
Kate Kerpen ◽  
Paraskevi Koutrolou-Sotiropoulou ◽  
Chencan Zhu ◽  
Jie Yang ◽  
Jennifer-A. Lyon ◽  
...  

Author(s):  
S Cherubin ◽  
T Peoples ◽  
J Gillard ◽  
S Lakhal-Littleton ◽  
J Kurinczuk ◽  
...  

BMJ Open ◽  
2021 ◽  
Vol 11 (10) ◽  
pp. e054994
Author(s):  
Julian Hoevelmann ◽  
Elani Muller ◽  
Ameer Hohlfeld ◽  
Michael Böhm ◽  
Karen Sliwa ◽  
...  

IntroductionPeripartum cardiomyopathy (PPCM) remains a major contributor to maternal morbidity and mortality worldwide. The disease is associated with various complications, which occur predominantly during the early stages of the disease. Adverse outcomes include decompensated heart failure, thromboembolic complications, arrhythmias and death. We present a protocol for a systematic review and meta-analysis to summarise the available data on the complications and outcomes of women with PPCM.Methods and analysisA comprehensive search of all articles published between 2000 (the year in which the first universal definition of PPCM was used) and 1 June 2021 will be performed on PubMed/MEDLINE, Web of Science, Scopus and EBSCO Host, including Academic Search Premier, Africa-Wide Information, Cumulative Index to Nursing and Allied Health Literature. All cohort and cross-sectional studies, as well as control arms of randomised control trials (RCTs) reporting on the complications and outcomes of PPCM will be included in the review. Methodological quality assessment of included studies will be done by assessing the risk of bias. Heterogeneity of the data will be tested by visual inspection of the forest plot and I2 and χ2 tests. This study will report the burden of complications occurring around the time of diagnosis as well as the 6-month or 12-month outcomes of women with PPCM. A summarised description in form of a pooled analysis of across multiple centres, regions and continents would help us to better understand the estimates of complications and outcomes of women with PPCM.Ethics and disseminationAs this research is a systematic review of published literature, ethical approval is not required. The results will be reported according to the latest guidelines for Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 statement, and will be submitted to a peer-reviewed journal.PROSPERO registration numberCRD42021255654.


Open Heart ◽  
2020 ◽  
Vol 7 (2) ◽  
pp. e001430
Author(s):  
Sinaida Cherubin ◽  
Taylar Peoples ◽  
Jessica Gillard ◽  
Samira Lakhal-Littleton ◽  
Jennifer J Kurinczuk ◽  
...  

ObjectivesWe conducted a systematic review and meta-analysis of studies that compared levels of molecular biomarkers in women with peripartum cardiomyopathy (PPCM) to those in healthy pregnant and postpartum women to: (1) assess the evidence for prolactin (PRL) metabolism in PPCM, (2) ascertain the evidence for biomarkers of iron deficiency in PPCM, (3) identify other biomarkers associated with PPCM.MethodsWe searched Medline, Embase, Cumulated Index to Nursing and Allied Health Literature (CINAHL) and the Global Health Library from inception without language restriction for studies that compared biomarkers levels in PPCM cases to healthy controls. Pooled standardised mean difference (SMD) was generated using a random effects model for the difference in levels of biomarkers.ResultsTwo studies assessed the association of PRL with PPCM, and reported that PPCM cases have higher levels of total PRL. No studies investigated iron metabolism in PPCM. Other biomarkers associated with PPCM included serum levels of natriuretic peptides (SMD=3.77, 95% CI 0.71 to 6.82), albumin (SMD=-0.67, 95% CI -1.01 to -0.32), C-reactive protein (SMD=1.67, 95% CI 0.22 to 3.12), selenium (SMD=-0.73, 95% CI -1.58 to 0.12), cardiac troponins (SMD=1.06, 95% CI 0.33 to 1.80), creatinine (SMD=0.51, 95% CI 0.33 to 0.69), white bloodcells (SMD=0.44, 95 % CI 0.07 to 0.82), haemoglobin (SMD=-0.45, 95% CI -0.64 to-0.26).ConclusionsMore robust molecular studies are needed to explore the association between prolactin and PPCM in human subjects and to determine the extent to which iron deficiency (with or without anaemia) contributes to the risk of PPCM.


2020 ◽  
Vol 26 (10) ◽  
pp. S24
Author(s):  
Veraprapas Kittipibul ◽  
Sunita Mahabir ◽  
Garly R. Saint Croix ◽  
Michael Ibrahim ◽  
Gabriel A. Hernandez ◽  
...  

2021 ◽  
Author(s):  
Yali Wei ◽  
Yan Meng ◽  
Na Li ◽  
Qian Wang ◽  
Liyong Chen

The purpose of the systematic review and meta-analysis was to determine if low-ratio n-6/n-3 long-chain polyunsaturated fatty acid (PUFA) supplementation affects serum inflammation markers based on current studies.


Sign in / Sign up

Export Citation Format

Share Document